ArticleMedical physics2026
In-Depth optimization and characterization of prostatic and penile vessel imaging with Ferumoxytol-enhanced magnetic resonance imaging.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVasculogenic erectile dysfunction (ED) arises from impairment of the vascular supply to the penis and requires reliable quantitative imaging for diagnosis, management, and longitudinal monitoring, particularly after pelvic surgery or radiotherapy. Penile Doppler ultrasound is a manual examination and subject to substantial inter-observer variability in both acquisition and interpretation. PURPOSE: To develop and optimize a Ferumoxytol-enhanced magnetic resonance angiography (MRA) protocol for noninvasive, high-resolution imaging of prostatic and penile vasculature, and to design and implement study-specific physical and in silico phantoms for quantitative evaluation under controlled line pair, anatomically realistic, and physiological conditions.
methodsImaging was performed on a 1.5 T MRI scanner using T1-weighted TurboFLASH and T2-weighted turbo spin echo sequences using Ferumoxytol doses of 1-4 mg/kg. Line pair phantoms containing tubes with 0.5-6 mm inner diameter and 0.5-5 mm spacing were constructed to span the size range of prostatic and penile arteries. An anatomically derived anthropomorphic phantom was fabricated by segmenting penile vasculature from a patient CT angiogram, 3D-printing the resulting geometry, and embedding Ferumoxytol-loaded tubing to reproduce realistic vessel tortuosity. Protocol performance was assessed using signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and modulation transfer function metrics (MTF50 and MTF10). Numerical simulations were also performed to evaluate sequence behavior under flow conditions.
resultsTurboFLASH was selected over TSE because Ferumoxytol-induced T1 shortening provided superior vessel conspicuity. Vessels larger than 1 mm were clearly visualized at all dose levels, with 2 mg/kg identified as the optimal dose. MTF50 indicated a nominal resolution of approximately 3 mm in both phantoms. MTF10 indicated effective resolutions of approximately 2 mm in the line pair phantom and 1 mm in the anthropomorphic phantom. Simulations demonstrated preserved contrast enhancement at a flow velocity of 100 mm/s.
conclusionFerumoxytol-enhanced MRA shows promise for visualizing major prostatic and penile vessels relevant to ED diagnosis and management, including the accessory pudendal and internal pudendal arteries. Further anthropomorphic phantom refinement and in vivo patient studies are warranted to evaluate broader anatomic variability and clinical feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.